Key highlights
- Today marks the official transition of Lundbeck’s commercial operations in the Middle East and North Africa (MENA) region to NewBridge Pharmaceuticals.
- The partnership ensures continuity of access to Lundbeck’s neuroscience portfolio for patients across the MENA
- Collaboration underscores NewBridge’s commitment to expanding access to innovative treatments in brain health.
NewBridge Pharmaceuticals (NewBridge) today announced the official transition and operational launch of its strategic partnership with H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company specializing in brain health.
Effective 1 November 2025, NewBridge assumes responsibility for the sales, marketing, access and distribution of Lundbeck’s neuroscience medicines across the MENA region.
The transition marks the beginning of a new phase in both companies’ collaboration and ensures that patients and healthcare professionals continue to have uninterrupted access to Lundbeck’s established portfolio of therapies addressing neurological and psychiatric disorders.
“Today we are proud to announce the official transition of our partnership with Lundbeck,” said Joe Henein, President & CEO, NewBridge Pharmaceuticals. “This milestone reflects our shared commitment to improving brain health and ensuring continued access to innovative neuroscience treatments across the MENA region. With our in-depth regional knowledge and expertise, we are excited to build on Lundbeck’s legacy and deliver sustainable value to patients and healthcare systems.”
This collaboration is part of Lundbeck’s broader global transformation to focus resources on high-growth opportunities while maintaining patient access in key markets through trusted regional partners.
“Our partnership with Lundbeck strengthens NewBridge’s mission to serve as a bridge between innovation and access,” added Joe Henein. “We look forward to working closely with Lundbeck to introduce future innovations in neuro-rare and neuro-specialty diseases in relevant markets, reinforcing our shared vision of improving lives through science and care.”
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals (NBP), a specialty company headquartered in Dubai Science Park, Dubai, United Arab Emirates, has been operating in the Middle East and North Africa (MENA) region since 2010. Today, NBP operates across 14 countries with offices in Saudi Arabia, Egypt, Kuwait, Lebanon, Algeria, and Morocco. Leveraging its first-in-class business model, NBP has emerged as a leader with a commercialization platform that brings global innovations to the MENA region, expanding patient access to advanced therapies. To achieve this mission, NBP partners with leading global biopharma companies, serving as their trusted one-stop solution for the MENA markets. For more information, please visit:
nbpharma.com
